跳至主要内容
临床试验/NCT03642821
NCT03642821已完成不适用

Intracranial Aneurysms Treatment With the OPTIMA Coil System

Balt Extrusion20 个研究点 分布在 7 个国家目标入组 300 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
20
主要终点
Morbi-mortality at 30 days

研究概览

简要总结

International, non-randomized, European , multicenter, observational study to collect data for the treatment of intracranial aneurysms with OPTIMA coils system to further document its safety and efficacy

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with small or large intracranial aneurysm, ruptured or unruptured, intended to be selectively treated with the OPTIMA coil system. Patients with recanalized aneurysms previously treated with coils exclusively are also eligible. Balloon and stent assisted coiling are allowed at index procedure.
  • In case of multiple aneurysms, patient can be included when only 1 aneurysm is treated during the procedure and none of the other aneurysms are treated up to 30 days post-procedure
  • Patient older than 18 years
  • Patient who has been informed of the study and has signed an informed consent form where applicable according to local regulations.

排除标准

  • 未提供

结局指标

主要结局

Morbi-mortality at 30 days

时间窗: 30 days

Rate of adverse events including thromboembolic events, the bleeding/rebleeding episodes, the rate of retreated aneurysm and the rate of mortality occurring during the procedure and up to 30 days.

Clinical outcomes (mRS) at 30 days

时间窗: 30 days

Classification of the patient clinical and neurological outcomes based on modified Rankin Scale from 0 (no symptoms a all) to 6 (dead). Global outcomes of mRS 0-2 are considered good and those of mRS 3-6 (including mRS 6 - deceased) are considered to be poor.

次要结局

  • Morbi-mortality at 12 months(12 months)
  • Clinical outcomes (mRS) at 12 months(12 months)
  • Aneurysm occlusion rate(Up to 24h and 12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验